drugset / Trial / NCT02823106

Superselective Citicoline and Verapamil for Ischemic Neuroprotection and Greater Effective Response

NCT02823106

Phase 1 Withdrawn Justin Fraser
RandomizedParallel-groupSingle-blindTreatment

Summary

This is a phase 1, blinded-outcome, randomized, placebo controlled study to investigate the safety and feasibility of super-selective intra-arterial administration of verapamil and citicoline immediately following successful endovascular thrombectomy as a potential neuroprotective synergistic therapeutic strategy in emergent large vessel occlusion stroke. This trial represents the first time that citicoline will be evaluated in human subjects as a superselectively administered neuroprotective agent administered in an acute time frame as an adjunct to intra-arterial thrombectomy. Furthermore, it will represent the first trial to evaluate combinational therapy for acute stroke neuroprotection.

Timeline

Start
2016-08
Primary completion
2016-09
Completion
2016-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Citicoline Other / unclassified 1000 mg Other
Subject Verapamil Other / unclassified 10 mg Other

Indications